尤瑞克林、丁苯酞和阿司匹林联合治疗急性脑梗死的临床研究

目的探讨研究尤瑞克林联合丁苯酞治疗急性脑梗死的临床疗效和安全可行性。方法我院神经内科收治80例72h发病的急性脑梗死患者，随机分成治疗组和常规组，各40例，两组给予相同的基础治疗（降压、降糖、调血脂、抗血小板聚集或抗凝药物、改善脑循环、营养脑细胞药物），但治疗组加用尤瑞克林0．15PNA单位静脉滴注，每131次，连用1～2周，丁苯酞软胶囊每次2片（0．1g，粒）．每日3次于治疗前后评定患者神经功能缺损程度、日常生活活动能力及不良反应事件。结果两组治疗前后3d、7d、14d、28d、90d的神经功能缺损评分以及90d后两组的神经功能缺损、日常生活活动能力均有所改善，与治疗前相比差异具有统计学意义（P〈0．05）；治疗组改善程度更明显，与常规组相比差异有统计学意义（P〈0．05）；治疗组较常规组不良反应无明显增加。结论尤瑞克林治疗能降低脑卒中发病率，有利于急性脑梗死患者神经功能恢复、提高日常生活活动能力，安全性可以肯定。

Urinary kallidinogenase,butylphthalide and aspirin in the treatment of acute cerebral infarction

Objective To explore the efficacy and safety role of UrinaryKallidinogenase joint butylphthalide in treatment of acute cerebral infarction.Methods Eighty patients with acute cerebral infarction within 72 hours of the onset were randomLy divided into Urinary Kallidin-ogenase group and routine treatment group,40 patients in each.The basically treatment of two groups were the same,including control blood pressure / glucose / LDL-C,anticoagulant drugs and given nutrition of brain cells.Urinary Kallidinogenase group was administered intravenous drip once daily for 7 days or 14 days with 0.15 PNA Urinary Kallidinogenase on the basis of routine treatment.The neurologic function deficits and ability of daily life of patients with acute cerebral infarctionand safety were evaluated before and after thetreatment.Results The difference of neurologic function deficits and ability of dailylife after treatment in two groups were improved,which compared with before treatmentwas statistically significant(P < 0.05).Urinary Kallidino-genase group improved more remarkably,compared with the routine treatment group was statist-ically different significance(P < 0.05).The treatment group than in the routine treatment group no remarkable increase in adverse reaction.Conclusion Urinary Kallidinogenase group can decrease the incidenceof acute cerebral infarction.and improve neurologic function deficit and ability of daily life and safety in acute cerebral infarction.